A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2015

At a glance

  • Drugs Indoximod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Acronyms D-1MT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jun 2012 Status changed from active, no longer recruiting to discontinued, due to lack of enrolment, according to ClinicalTrials.gov record NCT00730609.
    • 28 Jun 2012 Status changed from active, no longer recruiting to discontinued, due to lack of enrolment, according to ClinicalTrials.gov record NCT00730609.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top